

Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons

GW Infectious Disease Updates


GW Covid-19 Collection

12-9-2021

Covid-19 Clinical Update 12/09/2021

George Washington University

Follow this and additional works at: <https://hsrc.himmelfarb.gwu.edu/infectiousdiseaseupdates>



Lions and Tigers Continue To Recover From COVID-19 and First Vaccines Were Administered To Susceptible Species at Smithsonian's National Zoo

Oct. 15, 2021



COVID-19 UPDATE

HANA AKSELROD, MD, MPH

GW DIVISION OF INFECTIOUS DISEASES

MFA COVID-19 LEAD

12/09/2021



1. EPIDEMIOLOGY

2. TREATMENT

3. PREVENTION

4. GW UPDATES


New reported cases



Hot spots

AVERAGE DAILY CASES PER 100,000 PEOPLE IN PAST WEEK

10 30 50 70 100 250 FEW OR NO CASES



District of Columbia COVID-19 Daily Case Rate


per 100,000 population (7-day average)

Daily Case Rate:
per 100,000 population **23.2**



	Weekly Case Rate per 100,000 population	Daily Case Rate per 100,000 population	Hospitalization % of COVID-19 Cases	Contact Attempts among "high risk" cases	Interviews among "high risk" cases	Fully Vaccinated DC residents
Recent Value	162.4	23.2	7.0%	97.7%	86.2%	64.1%
One Month Prior	73.8	10.5	6.4%	99.2%	84.3%	62.5%
7 Day Trend	Worsening	Worsening	Worsening	Improving	Improving	Improving

There are signs that B.1.1.529 may be triggering a new wave in South Africa



Source: FT analysis of data from Gisaidd and the South African National Health Laboratory Service
© FT



Tedros Adhanom Ghebreyesus
@DrTedros

The Omicron variant reflects the threat of prolonged vaccine injustice. The longer we take to deliver [#VaccineEquity](#), the more we allow the [#COVID19](#) virus to circulate, mutate and become potentially more dangerous.



nature

Search Login

Explore content About the journal Publish with us

NEWS | 25 November 2021 | Update [27 November 2021](#)

Heavily mutated Omicron variant puts scientists on alert

Researchers are racing to determine whether a fast-spreading coronavirus variant poses a threat to COVID vaccines' effectiveness.

United States: 8/29/2021 – 12/4/2021

United States: 11/28/2021 – 12/4/2021 NOWCAST



USA

WHO label	Lineage #	US Class	%Total	95%PI
Delta	B.1.617.2	VOC	99.9%	99.8-99.9%
	AY.1	VOC	0.1%	0.0-0.1%
	AY.2	VOC	0.0%	0.0-0.0%
Omicron	B.1.1.529	VOC	0.0%	0.0-0.0%
Other	Other*		0.1%	0.0-0.1%

* Enumerated lineages are US VOC and lineages circulating above 1% nationally in at least one week period. "Other" represents the aggregation of lineages which are circulating <1% nationally during all weeks displayed.


** These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates

AY.3-AY.125 and their sublineages are aggregated with B.1.617.2.

Omicron: What Is Known*

- **Transmissibility:** similar to or higher than Delta?*
- Steep rise in cases in S. Africa, superspreader events in Europe
- Detected by current PCR (multiple targets; may distinguish S-target “dropout” on some) and antigen (conserved epitopes) tests
- **Ability to infect vaccinated or previously infected people**
- How does risk compare for vaccinated vs. not?
- What relationship to time since vaccination?
- Protection restored by booster?
- Neutralization studies:
 - Antibody neutralization in sera of vaccinated pts \downarrow 20-40x *
 - Pfizer: 3rd dose of vaccine improves neutralization \uparrow 25x *
 - mAb efficacy: REGEN-COV may be affected, GSK may be preserved? *
- **Severity of disease:** may be similar or milder?*

* “Publication by Twitter” and “expert opinion”
a.k.a. “written in jello”



Treatment and Prevention Updates

MOLNUPIRAVIR

- Updated MOVE-OUT data: 30% reduction in hospitalization (was 50% in interim analysis)
- Concerns about mutagenesis potential (see: <https://www.pharmaceutical-technology.com/features/molnupiravir-safety-questions-approvals-approach/>)
- FDA Advisory Committee split vote in support of approval; final decision pending

FLUVOXAMINE

- Promising study in *Lancet Global Health* but some issues with outcomes, see <https://www.the-scientist.com/news-opinion/a-closer-look-at-the-new-fluvoxamine-trial-data-69369>


EVUSHIELD (TIXAGEVIMAB + CILGAVIMAB)

FDA approved for **PrEP of COVID-19** in:

- Ages 12+, weight >40 kg
- **Not currently infected** with SARS-CoV-2 or within incubation period of a known exposure
- **Moderate to severely immunocompromised**, or
- Have a history of severe adverse reactions to a COVID-19 vaccine precluding vaccination with vaccine(s) approved for their age group

Prevention Recap

1. **Significantly immunocompromised:** need 3rd dose, given ≥ 1 month after #2.
2. **J&J recipients:** need 2nd dose, given ≥ 6 months after #1.
3. **Ages 16+: booster/3rd dose, given ≥ 6 months after #2. Can “mix & match.”**
4. **Combine multiple interventions** for optimal prevention.



GW Updates



- **COVID-19 Vaccine Clinic at 949 23rd St. NW**
 - <https://www.gwdocs.com/patients-visitors/covid-19-updates/covid-19-vaccination-information/> *
- **Monoclonal antibodies for high-risk infected:**
 - Available at GWUH ED
 - DHHS Locator: <https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients>
 - Availability of new AZ mAb for PrEP: TBD
- **Safety advisory:**
 - **Low threshold of suspicion to re-test inpatients.**
 - Holiday celebrations: Swiss Cheese
 - Encourage family to get boosters.
 - Consider pre-ordering rapid tests.
 - GW campus testing: <https://mychc.gwu.edu/> *

* Check for holiday closures

An official website of the United States government
Here's how you know

COMBATCOVID

Español

Possible Treatment Options for COVID-19 COVID-19 Clinical Trials COVID-19 Vaccines Clinical Trial Toolkit for Healthcare Professionals Monoclonal Antibodies Resources for Healthcare Professionals News & Media Resources About Combat COVID

MONOCLONAL ANTIBODIES FOR HIGH-RISK COVID-19 POSITIVE PATIENTS

Contact the Combat COVID Monoclonal Antibodies Call Center:
1-877-332-6585

If you've tested positive for COVID-19, one of the first questions you may have is, What can I do to reduce the risk of getting sicker? The good news is, there are treatments that may reduce that risk. Depending on your age.

FEATURED NEWS

mAb Treatment Locator

Top

<https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients>